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ABSTRACT
Objectives: Pharmacoeconomics and outcomes research
have the potential for rapid adoption in the Asia Paciﬁc
region. Nevertheless, the region is characterized by great
diversity in social and economic development, ethnicity,
population size, health-care system, culture, language,
and religion. Thus, the rate of adoption is also quite
diverse across the region.
Methods: Among the countries reviewed in this article,
governments take varying levels of interest in applying
this research in health policy decisions. For example,
some countries have already implemented systems that
require pharmacoeconomic studies as one component of a
new pharmaceutical product’s approval for reimburse-
ment, whereas others recommend such data but do not
require it in policy and medical decision making. The lit-
erature in the countries reviewed is actually quite robust
given the early stages of development of this ﬁeld in most
countries. The academic community has members trained
in this ﬁeld of research in all the countries reviewed and
some universities have established departments whereas
others have just introduced a few classes in the area.
Results: At the moment, pharmacoeconomics and out-
comes research are being conducted mainly by academics.
In addition, some pharmaceutical researchers are active
and pharmaceutical companies are currently preparing to
conduct more of this research as part of their strategy for
Asian drug development.
Conclusions: Prospects for future growth and develop-
ment in this ﬁeld are quite good in Asia as rapid health-
care inﬂation, increasing rates of chronic conditions and
aging population, and increasing technology diffusion
will underpin the need for greater awareness of the need
to incorporate economic efﬁciency into the health-care
systems.
Keywords: Asia, outcomes research, health care,
pharmacoeconomics 
Introduction
Between 1960 and 1990, Asia experienced rapid
economic development, and despite the recent eco-
nomic downturn, it remains important in the world
marketplace, especially in health care and pharma-
ceutical consumption. For example, as a single
country, Japan has the second largest pharmaceuti-
cal market second only to the United States. Never-
theless, many countries in the region now face
ﬁnancial difﬁculties that make paying for health-
care services, including pharmaceutical products,
challenging.
The concepts of pharmacoeconomics (PE) and
outcomes research (OR) were introduced in west-
ern countries in the 1970s and formal PE guide-
lines were ﬁrst established in Australia and
Canada about a decade ago [1,2], in response to
rapid health-care cost inﬂation. Asia too, though
slightly later in time, now must respond to the
typical factors that drive increasing health-care
expenses such as an aging population, increased
rates of chronic diseases and disabling conditions,
changes in health-care technology, and increasing
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payments from third-party payers [3]. As such, PE
and OR activities have become increasingly visi-
ble in Asia [4], yet one wonders how far these
trends will proceed? Will PE as an evaluation tool
for health-care decision making eventually be uti-
lized in Asia to as great an extent as in western
countries? To discuss this question, a Panel Dis-
cussion on Outcomes Research in Asia was organ-
ized (International Society of Pharmacoeconomics
and Outcomes Research (ISPOR) 7th Annual
International Meeting, 2002), and this article ex-
pands on that session with a focus on the role of
PE and OR in the current health-care systems in
China, Hong Kong, Japan, Korea, Singapore, and
Taiwan.
China
In China, PE and OR are not widely used in either
the public or the private sectors because pharma-
ceutical policy and medical decision making are
still dominated by traditional approaches focused
on clinical efﬁcacy, safety, and price considera-
tions. Nevertheless, given the large population
base, strong economic growth, and recent health
policy reforms, one cannot underestimate the
growing need for PE and OR. For example, PE or
OR data may play an increasing role in recent
important reforms, including expanded health
insurance coverage, creation of a national drug
formulary, the separation of drug dispensing from
prescribing, a new drug pricing system, and
China’s entry into the WTO.
Although most of rural China is still without
health insurance, urban health-care programs are
transitioning into community-based insurance sys-
tems aimed at increasing the insurance risk pooling
covering an estimated 80 million urban employees
in large cities, accounting for approximately one-
third of the urban population nationwide [5–8]. It is
expected that increasing public efforts will be made
to extend the coverage for most of the employed
sometime around 2003 to 2004 through the new
insurance program.
In 2000, China’s national health-care expendi-
tures were US$57.4 billion. Although this ﬁgure
does not seem very high compared to that of many
developed countries, the annual rate of growth has
been well over 10%, far higher than the GDP
growth rate in the 1990s [9]. This has led to a
steady increase in the share of GDP on health-care
expenditures, up from 3.5% in 1990 to 5.3% in
2000 [10], and this trend is anticipated to continue
for the years ahead.
In 2001, sales of pharmaceutical products
and services in China totaled US$33.3 billion, up
18.5% from 2000. This growth was higher than
that of most other sectors in the economy.
Demand for medication use in China is extremely
high relative to the overall economy and total
health-care spending [11]. This will likely con-
tinue owing to several factors. First, drug expendi-
tures consume more than half of the total health-
care budget in China. This is in sharp contrast
with many other countries. For instance, in the
United States, drug expenditures account for total
health-care costs in the range of 8.7% in 1980 to
10.8% in 1999. During the same time period, the
drug share of the total health-care budget in
China ranged from 65% to 58% as shown in
Fig. 1 [12].
Second, there is a strong income effect. During
the 1990s, while annual economic growth rates
ranged from -0.5% to 4.5% in the United States
and 1.4% to 3.9% worldwide, China was among
the few countries that maintained a much higher
growth rate of 4.0% to 14.3% [10]. If such a trend
continues in the future as is widely anticipated, this
will entail a signiﬁcant income effect on demand for
health-care and medications [13].
Third, the population is rapidly aging. In the
early 1980s when the 65 years and over cohort was
about 6% of the total population worldwide,
China’s elderly population was only 4.7%. In the
year 2000, however, this ﬁgure in China reached
almost the same level of the worldwide average at
7% (Fig. 2). Moreover, population census data sug-
gest that over the next few decades China will face
an even more rapid aging trend.
Figure 1 Prescription share of  national health-care expenditures.
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Pharmacoeconomic Studies in the Literature
Although pharmaceutical expenditures account for
a major part of total health-care expenditures in
China, little use has been made of PE in health pol-
icy and medical decision making until very recently
when China launched several health-care system
reforms. In the late 1990s, the concepts of PE and
OR were increasingly introduced in China through
many channels, mostly via training seminars, con-
ferences, fellowships, and some actual studies. To
better understand the current research capacity of
pharmaceutical OR in China, we conducted an
online search of China’s pharmaceutical literature
database using the key words “pharmacoeconom-
ics” and “outcomes research.” The preliminary sta-
tistics are as follows:
Without an in-depth review of each article, we
found a total of 426 papers containing the key
words, ranging from 117 in year 1999 and 106 in
2000 to 203 in 2001. In a recent review study, Liu
[14] speciﬁcally analyzed the characteristics of 45
PE papers. Their data indicated that most of the
studies were conducted by pharmacists (60%), fol-
lowed by medical doctors (20%), college professors
(9%), and all others (11%). Researchers in govern-
ment agencies or industry did not seem to play
much of a role in conducting these studies. Of the
45 papers, 18 were prospective studies, 12 were ret-
rospective, and 15 were review studies. In terms of
methodology, cost-effectiveness analysis is the most
popular approach. This is consistent with our brief
review of 39 papers published in the ﬁrst half of
2002, in which 21 papers used cost-effectiveness
methods, 3 used cost-minimization analyses, and
none used cost-utility or cost-beneﬁt analysis. The
remaining papers were on theoretical discussions,
policy debates or market analyses or were an intro-
duction to international research in this ﬁeld.
Prospects for the Future
The following major initiatives and developments
are likely to drive the future use of PE and OR data
in policy and medical decision making in China:
Urban Health Insurance Reform and Essential
Drug Formulary (EDL) The Ministry of Labor and
Social Security (MOLSS) administer the health
insurance system and recently the drug formulary
has been speciﬁcally targeted for cost savings. The
drug formulary consists of two essential drug lists
(EDL A and B). EDL A includes drugs deﬁned as
“clinically necessary, widely used, safe and efﬁca-
cious; and price advantageous among its class”
[15]. EDL A is a national list and cannot be modi-
ﬁed by local governments. EDL B is deﬁned simi-
larly to EDL A except that prices are generally
higher than similar drugs in EDL A. Local govern-
ments are allowed only to modify EDL B up to 15%
of the total number of drugs included in the original
list. Although cost-effectiveness was not part of the
criteria for EDL selection, the recent revisions in the
government EDL guidelines explicitly ask for the
involvement of health economists in the determina-
tion of the EDL. Some foreign drug companies
already are voluntarily submitting PE data along
with their conventional submissions to MOLSS for
EDL consideration.
Pharmaceutical Pricing In July 2002, The State
Planning Commission issued a policy document
titled “Reforming Pharmaceutical Pricing Manage-
ment,” which established two mechanisms for
pricing pharmaceuticals. One is a centralized gov-
ernment pricing of all drugs on the EDL based on
drug production costs. This establishes a baseline
price for each drug as a national reference. Capped
at the baseline reference level, actual retail prices
can vary downward, allowing retailers to make
more competitive pricing. For drugs not on the
EDL, in contrast, the pricing is primarily left to the
determination of market demand and supply. From
the government’s perspective, the current cost-
driven pricing of EDL drugs is considered subopti-
mal, and it appears that cost-effectiveness will
ultimately serve as the primary basis for pricing as
a means of better allocating health-care resources.
WTO Entry and Its Impact The pharmaceutical
industry, subject to many unique regulatory condi-
tions, patent protections, and international trade
constraints, will be greatly affected by China’s entry
into the WTO. Following WTO agreements, China
will allow foreign vendors to operate in a number
of important goods and service markets, including
Figure 2 Percentage of  population over 65 years of  age.
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drug distribution, pharmacy, and medical insur-
ance. This, in addition to the reduction of trade bar-
riers, will help the Chinese pharmaceutical market
to become much more competitive, likely following
international trends wherein PE data are utilized to
assess the relative value of competing medical tech-
nologies. In the past, few foreign companies oper-
ating in China have taken major initiatives to lead
the development of PE and OR; but this seems to be
changing with some recent efforts of drug compa-
nies to support PE and OR research and training
projects in collaboration with universities.
Other Government Initiatives In January 2001,
MOLSS issued a new policy on the management and
classiﬁcation of prescription and nonprescription
drugs [15]. This policy prohibits advertising for
prescription drugs in any public news media.
Because most EDL drugs are prescriptions, this pol-
icy challenges drug manufacturers to ﬁnd alternative
ways to demonstrate the value of their prescription
drugs to the payers. Pharmaceutical OR may be such
an alternative, especially for foreign drug makers
with higher priced products. Other areas of poten-
tial use of PE data could include premarketing
activities. These activities include early selection,
research and development, and drug approval with
the State Drug Administration (SDA). In fact, the
SDA National Center for Drug Evaluation has
recently suggested that PE assessments be consid-
ered in preparing phase IV clinical trails.
Hong Kong
Traditionally, the Hong Kong government, despite
its low taxation rate, has been committed to pro-
viding health care to all its citizens. More than 95%
of the total medical expenditures in Hong Kong have
been shouldered by the government, which has
maintained a health-care system comparable to that
of western developed countries in many aspects. As
a result of the rapid growth in the economy in the
past decade, there has been a corresponding growth
in demand for health-care services in Hong Kong.
The aging population has also become a major fac-
tor underpinning an increase in the demand for
intensive and long-term geriatric medical care. The
economic downturn in recent years has, not unex-
pectedly, put severe restrictions on the government’s
ability to maintain this model of health-care delivery.
The Hong Kong government has a long-standing
history of providing nearly free health care for all cit-
izens, irrespective of ﬁnancial status and of the gov-
ernment’s budget. The recurrent public health care
expenditure has comprised approximately 15% of
the government’s total public expenditure [16].
Though admirable, after many years of operation,
the situation is slowly coming to a dead end.
Over the past decade or so, spending on health
care in Hong Kong has been around 5% of GDP
[17]. Nevertheless, the estimated annual budget as
percentage of GDP is only 2.5% and, hence, there
has been a consistent overspending. Major factors
contributing to overspending include:
1. Heavy subsidization of inpatient and outpatient
services;
2. Abuse of accident and emergency services that
are free for all local citizens; and
3. Increased share of inpatients compared with the
private sector.
There have been numerous debates as to what
the future direction of the government’s role should
be. Yet the single most urgent question is, “How
long can this system be sustained?” Therefore,
although often praised by overseas counterparts as
one of the most admirable and generous providers
of health-care services, the Hong Kong Hospital
Authority (HA), which is a solely government-
funded organization, assumes the role both of the
provider and of the payer of health-care services. At
the moment, decision makers in Hong Kong, as in
some western countries as well, decide on choices of
medications or procedures with considerations
given mainly to safety, efﬁcacy, and their unit costs
rather than their long-term cost-effectiveness, and
only a few senior doctors with little scientiﬁc and
clinical evidence often carry out therapeutic substi-
tutions empirically.
To address more speciﬁcally the future health
needs of Hong Kong, a Health Care Reform Con-
sultation Document was prepared and released by
the Hong Kong government in December 2000.
Among the proposals, it was suggested that medical
technological progress should be effectively
exploited to the optimum advantage of the commu-
nity [16]. All of these issues have led to an impor-
tant landmark in the health-care history of Hong
Kong: an upcoming overall health-care reform in
which our ﬁnite resources will have to be spent in a
targeted and cost-effective manner.
Globally, PE data are the most effective tools in
decision making during the process of selection of
formulary choices or procedures. At the moment,
local ofﬁcials tend to focus on addressing the acute
crisis rather than the long-term effects of health-
related problems. Conceptually, the word “cost-
effective” is often used, either consciously or sub-
consciously, to describe a drug or procedure that
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would cost less, yet the true long-term value of it in
comparison to the existing alternative often remains
unclear. Hence, the unit prices of drugs often take
precedence over their long-term cost-effectiveness in
decision making.
At the moment, formulary decisions for the pub-
lic sector are the primary responsibility of the Drug
Advisory Committee under the Hong Kong Hospi-
tal Authority. Among the information required in
new drug applications are data in relation to PE
analysis, yet there is no requirement as to where the
data should be generated. Nevertheless, it is gener-
ally recognized that declined applications are usu-
ally not due to lack of relevant PE data or their
quality. Hence, the proper utilization of PE data in
the government hierarchy in Hong Kong remains to
be further enhanced.
Despite this, many activities pertaining to PE
have been introduced in recent years; the driving
force has been mainly from the pharmaceutical
industry and academics. PE and OR studies started
to emerge around 1999. So far, more than 20
projects have been completed with at least 8 of them
published in top international peer-reviewed medi-
cal journals. An additional 20 or so abstracts have
been presented at international meetings. Among
the completed projects, quite a large proportion of
them are in the gastrointestinal area [18–20]. As a
result, the subject of PE has begun to receive atten-
tion from many different directions including the
government, the medical profession, the econo-
mists, and the media. Nonetheless, public aware-
ness in this area still needs to be substantially
increased.
The Perspective from Academia
Despite this lack of encouragement and clear recog-
nition from the government, local academics and
some health-care practitioners have been extremely
active in PE and OR activities. Apart from initiating
PE and OR studies of their own, academics in Hong
Kong have been participating, and in a few cases
acting, as the major driving force in international
multicenter PE studies.
In December 2000, a few of these active mem-
bers, with the support of ﬁve multinational phar-
maceutical companies, established the Chinese
Chapter of the International Society for Pharma-
ceconomics and Outcomes Research (ISPOR) in
Hong Kong, the ﬁrst regional chapter of the Society
in the Asia Paciﬁc area.
Since its establishment, close links have been
maintained with the local authority as well as ofﬁ-
cials in Mainland China. The Chapter has pub-
lished regularly in the Chinese Medicine Economic
News, which is one of the most widely circulated
health-care periodicals in China. Because the sub-
ject is still in its developing stage, only a few insti-
tutions have the expertise and infrastructure to
perform studies of their own. With the rapid devel-
opment of the discipline worldwide and the dedica-
tion of the local academics, it is anticipated that it
will only be a matter of time before PE and OR
studies will gain their recognition and status in the
health-care system. Academics should therefore
take a proactive role in advocating the use of PE
and OR data and their value in assisting the deci-
sion-making process both at the university and at
the government levels.
Japan
At present, PE is still at an early stage of evolution
within the health-care scene in Japan. This is in part
due to institutional factors related to how health-
care policy is formulated in Japan and also to the
incentives, or lack thereof, for delivering cost-
effective medical care. Historically speaking, Japan
has not put much emphasis on analytical assess-
ments in the formation of health-care policy. Policy
making has instead been more a process of consen-
sus building among all the key stakeholders [21,22].
Having said that, there has been a recent show of
interest by the government in improving the health
services research infrastructure in Japan. For exam-
ple, in health economics, several formal programs in
academic and quasi-governmental institutes have
been established to collect analytical health eco-
nomics or PE data. The Institute for Health Eco-
nomics and Policy, originally funded by the
Ministry of Health (MHLW) in 1993, was estab-
lished “to survey and research health economics
and to collect and supply information on the subject
in order to contribute to the development of medi-
cal services and health policy in Japan” [23]. Also,
the University of Tokyo established in 2000 the ﬁrst
Division of Pharmacoeconomics in Japan [24].
Health-care decision makers do not regularly
require PE data because in Japan’s fee-for-service
(FFS) system of MHLW-established medical care
reimbursement rates [25] few economic incentives
exist at the provider level to promote cost-effective
delivery of health care. This may explain the histor-
ically high average hospital length of stay in Japan,
which in 1996 was 40.8 days [26,27].
Recent health-care policy initiatives indicate,
however, a greater interest in promoting cost-
effective delivery of health care as a means of con-
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trolling runaway health-care inﬂation and, thus, a
greater role for PE is beginning to emerge [28].
Also, since 1994, one area where PE has been reg-
ularly used is in price negotiations for newly
approved pharmaceuticals. The price of all prescrip-
tion drugs in Japan is determined by the MHLW,
and the MHLW in 1994 recommended that all new
drug applications contain a section on PE [29]. The
impact these data have had in actual pricing nego-
tiations is still somewhat unclear, and no PE guide-
lines exist yet, but the incentive for companies to
conduct these studies is rather strong.
Pharmacoeconomic Studies in the Literature
A review of the published literature on PE was
recently conducted and a total of 68 publications
were found for the period 1980 to 2001 [30]. In this
review, Doherty and Sato [30] found that the exist-
ing PE literature is quite broad in its application of
numerous methodologies: 54 of the 68 were cost-
effectiveness studies, 16 were cost-consequence
studies, and 11 were cost-beneﬁt analyses. The
authors also concluded that clinical trials, observa-
tional databases, patient medical charts, patient
bills, expert opinion, and other such data sources
are all available in Japan; however, some of these
sources are in limited supply. Furthermore, with
regard to medical care cost data in Japan, the
authors point out that the MHLW-determined sys-
tem of reimbursement fees can readily be used in PE
analyses to indicate the cost of various medical
treatment alternatives to the MHLW’s health insur-
ance system. Keeping in mind that drug pricing
decisions also take place within the MHLW, an eco-
nomic analysis using these MHLW fee data would
seem particularly useful in the drug pricing process
[30].
The Perspective from Academia
PE, as an academic discipline, was introduced to
Japan about a decade later than other industrialized
countries. At the “First International Symposium
on Clinical Economics” in 1989, international
researchers such as Drs. George Torrance, Milton
Weinstein, and Bengt Jönsson prepared a seminal
symposium for Japan’s academic community. An
introduction to PE was provided and, subsequently,
a research interest group on clinical economics was
organized in Japan. Also, the Japanese Ministry of
Health and Welfare started funding the Institute for
Health Economics and Policy to stimulate and
develop new research activities in Japan, and a
number of locally organized PE study groups were
established.
Although this initial burst of activity seemed
quite promising, the academic activities in PE have
not developed as quickly as had been expected. One
reason has been the conservative environment of the
leading universities, most of which are national uni-
versities, which lack the ﬂexibility needed to adjust
quickly to such new challenges and opportunities.
Another impediment has been the traditional dom-
inance of the medical community, in all aspects of
medical research, to the exclusion of public health
researchers, pharmaceutical department research-
ers, and pharmaceutical company scientists. Finally,
a lack of an interdisciplinary environment in Japa-
nese universities is another factor that slowed the
development of PE studies since this ﬁeld is typically
taught in Schools of Public Health, which by their
nature offer an interdisciplinary environment that is
rare in Japan. In addition, Japan’s academic out-
comes researchers have been discouraged by the
poor capability of university-afﬁliated information
systems, which are insufﬁcient to conduct reliable
outcomes studies.
Despite these impediments, researchers are
actively preparing for a new era of PE and OR in
Japan. In fact, ISPOR, a leading international OR
organization with strong academic ties, held an Asia
Paciﬁc meeting in Kobe, Japan, in September 2003.
Prospects for the Future
Upcoming health-care reforms may have a direct
impact on the demand for PE data. For example,
introduction of a nationwide diagnosis-related
group (DRG) system could abruptly increase the
demand for PE data. In fact, recently, a DRG-type
payment system was implemented at all National
University medical hospitals called the Diagnosis
Procedure Combination system (July 2003). Addi-
tionally, nationwide DRG demonstration studies
involving around 300 hospitals are at present under
way and are scheduled to conclude in 2003.
In Japanese universities, two other major move-
ments are afoot that should impact PE research: 1)
an administrative readjustment of National Univer-
sities and 2) an awareness of evidence-based medi-
cine among medical professionals. All national
universities are readjusting their administrations
into a new quasi-public system designed to have the
ﬂexibility of a private university. During such tran-
sitions opportunities exists for policy makers to
break through existing barriers to introduce a
greater awareness of the importance of medical care
efﬁciency.
Such an awareness of health-care care efﬁciency
within the medical community is already being
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accelerated by the recognition of the usefulness of
evidence-based medicine (EBM). It is in this context
that some of the leading national universities, such
as the University of Tokyo, Kyoto University, and
Kobe University, have been developing the various
graduate training programs related to PE. This
awareness of EBM is expected to grow in the com-
ing decade.
Drug pricing reform is another important topic
in Japan. The new Drug Pricing Organization
(DPO) established in 2000 reiterated its willingness
to accept PE data as one element to be considered in
their pricing decision, and one board member is an
economist. It is important to note that PE research
that establishes the relative value of a new drug
compared to existing treatments may be used to jus-
tify a premium prices for new drugs at the DPO.
According to a recent survey of the conditions of PE
studies at pharmaceutical companies in Japan, 47%
of surveyed companies use PE data in their drug
pricing negotiation process, and 77% actually
acknowledged the value of this data. Nevertheless,
these same respondents were not certain just how
inﬂuential these data are at the MHLW at present
[31]. If the Japanese government would disclose the
process of how it uses or plans to use the PE data in
pricing or reimbursement decisions, then this would
give some needed guidance to companies and
researchers. Overall, the ﬁeld of PE in Japan has
great potential for growth and as the need for these
data continues to increase so too will the demand
for better sources of underlying raw data and more
academic programs in the ﬁeld.
Korea
The Korean health-care system is a market-
oriented, private-sector-dominated, FFS payment
system. The role of the government has been limited
primarily to the public health area with little regu-
lation or monitoring of the ever-growing number of
private providers.
The system is market-oriented in the sense that
health care is viewed as an economic good, but not
as a social good. With high levels of copayment and
special charges, the amount and level of care one
receives depends largely on income level. For exam-
ple, there are designated treatment charges (DTCs).
When patients prefer to be treated by regular staff
physicians, or board specialists, in a general hospi-
tal, they are supposed to pay DTCs on top of the
scheduled fees. If they cannot afford the DTCs,
interns or residents are automatically assigned to
them.
FFS has been the dominant method of payment
for physicians, clinical services, and pharmacists.
Case-based payment (called DRGs) experiments
began in early 1997. Already, a DRG system is
being used for some inpatient cases, but only on a
voluntary basis. Physicians at hospitals are paid sal-
aries, and occasionally they are paid performance-
based bonuses.
Health Insurance
Started in 1989, the Korean National Health Insur-
ance (NHI) program covers all citizens on a
compulsory basis. The National Health Insurance
Corporation [32], a single payer, collects premiums
through employment payroll deductions for the
employed and through a means test for the self-
employed to ﬁnance the NHI.
Providers are paid by FFS in return for providing
services that are covered by insurance. Total
expenses are reimbursed, in part, by the insurance
funds. The remaining cost is paid through patients’
out-of-pocket payments. Two types of cost-sharing
features are found. The ﬁrst feature is a deductible,
applied to each unit of service. On top of the
deductible, a patient pays coinsurance rates of 30%
for clinic outpatient services, 50% for hospital out-
patient services, and 55% for general hospital out-
patient services. The coinsurance rate for inpatient
services is 20% across all types of providers. Under
the NHI, for insurance-covered services, providers
(hospitals and clinics) are reimbursed according to a
set of fee schedules. The government plays a major
role in setting the fee schedules, although stakehold-
ers negotiate the level of fees at the national level.
Drugs account for a relatively high percentage of
health insurance expenses, for example, 33% in
1997. Historically, the prescription and dispensa-
tion of drugs were both handled by providers.
Nevertheless, as part of a pharmaceutical reform
and cost control effort, the Korean government
launched a new system that as of July 1, 2000, sep-
arated prescribing and dispensing medication. In
addition, to curb escalating drug costs, a new reim-
bursement system of drug prices, actual transaction
pricing (ATP) system, was introduced in November
1999. ATPs are the real drug prices that are trans-
acted between pharmaceutical manufacturers and
health-care providers, mostly clinics and hospitals,
upon purchase of drugs. Formerly, the prices of
drugs reimbursed to physicians and pharmacists
were government-approved ceiling prices. Under
the ATP system, from November 1999, health
insurance reimburses the lower of the two: govern-
ment ceiling prices or ATPs. By regulation, hospitals
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are required to report ATPs periodically to the
health authority.
Since September 1, 2002, submission of eco-
nomic data has been required by the health insur-
ance authority to determine reimbursement prices
for new drugs. Before this regulation, to have a bet-
ter position in pricing decisions, some pharmaceu-
tical companies voluntarily prepared economic data
for their key products and submitted them to the
health authority upon suggestion. Nevertheless, it is
not known how much impact the economic data
played in the determination of reimbursement
prices of new drugs, and there is little publicized evi-
dence available in this regard.
Pharmacoeconomic Studies in the Literature
Results from several PE studies have been publi-
cized to date. They are classiﬁed into two types: cost
analysis and cost-effectiveness analysis (CEA). A
study by Yang et al. [33] on hepatitis B is of the ﬁrst
type and examined the direct and indirect costs of
diseases related to hepatitis B in Korea. Another
cost analysis investigated the direct and indirect
societal costs of diseases related to osteoporosis
[34]. One can ﬁnd several other PE studies within
the framework of CEA [35–40].
Most PE studies rely on the following data
sources. For clinical probabilities and epidemiology,
Korean studies and population statistics are used,
when available. If not available, statistics from for-
eign studies are used as references. In this case,
meta-analysis and/or expert opinion are also
employed in modifying the foreign probabilities and
epidemiology data.
Cost Data in Korea
For cost data, the NHI database contains informa-
tion regarding claims for reimbursed medical serv-
ices, by diagnosis. The data are on a per-person
basis. Patients with a certain disease often make
copayments for medical services and buy additional
services that are not reimbursed by the NHI (e.g.,
magnetic resonance imaging, ultrasound, herbal
medicines, medicines bought over the counter from
pharmacies, dietary supplements, and auxiliary
nursing care). Patient charts are used to assess the
level of copayments for medical services that are not
covered by health insurance. Patient questionnaires
are often used to capture costs of nonwestern med-
ical services and of nonprescribed medicines.
In summary, the NHI database:
• Captures the total number of patients in each
disease category;
• Captures the total number outpatient visits and
inpatient days in each disease category; and
• Captures insurance reimbursements and patient
copayments in each category.
• Does not show other out-of-pocket payments
and patient charts;
• Does not capture noncovered services and costs
incurred in hospitals/clinics; or
• Does not capture all other payments for treat-
ment, including spending on oriental medicine.
The Government’s Perspective
Rising health costs are now viewed as a serious
problem in Korea. From 1975 through 1995, the
health-care share of the total economy (GDP) has
grown from 2.8% (1975) to 5.4% (1995), with an
annual rate of increase of around 28%. Between
1975 and 1995, the Korean economy recorded
unprecedented high growth rates. The increasing
share of health costs as a proportion of GDP there-
fore signiﬁes how fast the health sector expanded
during this period [41]. The continuing increases in
treatment costs in health insurance have reduced
accumulated surpluses. Finally, the health insurance
fund fell into deﬁcit in 2001.
The Korean government thus strove to ﬁnd ways
to contain health care costs. Both macro and micro
reforms are now being considered. One micro meas-
ure targets the growing pharmaceutical expendi-
ture. As part of this effort, a new rule to determine
maximum reimbursement prices for new pharma-
ceuticals was recently proposed in June 2002 by the
Ministry of Health and Welfare. In September 2002,
after a public hearing process, a new regulation was
ﬁxed and is now being enforced. This regulation
requires that economic data be submitted along
with the clinical data for drugs that are newly man-
ufactured by Korean companies as well as drugs
that are used overseas but waiting to be approved
into the Korean market. This is a rather big change
for pharmaceutical companies who are about to
introduce a new product into the Korean market. A
guideline for PE studies to be used in new drug pric-
ing is currently under preparation by the Health
Insurance Review Agency (HIRA), using foreign
guidelines as reference and a special committee was
formed to determine new drug prices, using pub-
lished PE guidelines.
A concern arises with regard to the new regula-
tion. There is an apparent lack of research capacity
for PE or OR on the part of universities, govern-
ment agencies, research institutions, and pharma-
ceutical companies. Therefore, a balanced approach
by the health authority in terms of law enforcement
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and research capacity building is highly desirable at
this moment.
Prospects for the Future
Even with the positive results from consolidation of
insurance funds and adoption of a drug dispensing
separation policy, experts argue that several basic
problems remain unsolved in the Korean health-
care system. Two major problems are limited insur-
ance coverage, especially in cases of major risks,
and cost increases that precipitate ﬁnancial insol-
vency in the health insurance system. Both macro
and micro reforms are essential for a sustainable
health insurance system, controlling expenditures
and increasing efﬁciency, by a strengthened role of
payers, increased accountability of purchasers, and
better purchasing agents. Placing budgetary caps on
expenditures is one option being considered as a
long-term strategy.
Whether future health reform is in the form of
DRGs, global budgeting, capitation, or any other
type, as long as it is targeted to gains in efﬁciency in
health ﬁnancing, the number of PE studies used for
health policy in Korea will increase. Because this is
highly likely, concerted preparation by all parties
involved is indispensable.
Singapore
Singapore is an island republic with a population of
approximately 4 million [42]. The population is
aging rapidly and the percentage of elderly is pro-
jected to increase to 27% by the year 2030. Given
the trend of aging population, the health status indi-
cators (Table 1), and the leading causes of morbid-
ity and mortality, mainly noncommunicable
diseases including cancer, cardiovascular disease,
stroke, diabetes, and injuries (with cancer and car-
diovascular disease accounting for about 62% mor-
tality), the problems in health-care delivery in
Singapore are similar to those in developed econo-
mies [43].
The total health-care expenditure in 1999 was
SIN$4.3 billion or 3% of GDP, with the govern-
ment subsidy on public-health-care services being
SIN$1089 million, or 0.8% of GDP (1998) and
SIN$919 million or 0.6% of GDP (1999) [44]. In
Singapore, health-care delivery and management is
under the purview of three ministries, namely, Min-
istry of Health (MOH), Ministry of Environment
(ENV), and Ministry of Manpower (MOM)
(Table 2), with the Ministry of Health as the minis-
try responsible for provision of preventive, curative,
and rehabilitation services; formulation of national
health policies; coordination of the development
and planning of the public and private health sec-
tors; and regulation of health standards (Table 2).
In addition to the provision of funding to the
public hospitals, the Ministry of Health in Singa-
pore has maintained a Standard Drug List (SDL)
since 1979. The SDL is essentially a national for-
mulary for the public-health-care institutions in Sin-
gapore. It lists all drugs that will be subsidized by
the government for its citizens and permanent resi-
dents. It is modeled after the WHO Essential Drug
List (EDL) with modiﬁcation to suit local disease
patterns.
According to the deﬁnition used by the MOH, a
standard drug is deﬁned as a drug that is necessary
for the treatment of a common ailment. Standard
drugs are usually essential ﬁrst-line drugs in a spe-
ciﬁc therapeutic class. At present, there are two
categories of standard drugs in Singapore:
Standard Drug List I (SDL I)
These drugs are considered as essential and cost-
effective ﬁrst-line drugs required by many patients.
Standard Drug List II (SDL II)
In 1992, the Ministry introduced this new category
of drugs into the SDL. The aim initially was to make
Table 2 Ministries managing health-care delivery in South Korea
Authority Health-care and public-health-related functions
Ministry of  Health (MOH) Provides preventive, curative, and rehabilitation services
Formulates national health policies
Coordinates development and planning of  public and private health sectors
Regulates health standards
Ministry of  Manpower (MOM) Responsible for industrial and occupational health of  workers
Ministry of  Environment (ENV) Responsible for environmental health services
Table 1 Health status indicators in South Korea (1999)
Infant mortality rate per 1000 live births 3.2
Life expectancy 77.6 (women),
71.9 (men)
Fertility rate (number of  live births per woman) 1.75
Hospitalization rate per 1000 population 96
Average length of  stay in acute hospital (days) 5.1
Doctors-to-population ratio 1:730
Hospital beds-to-population ratio 1:330
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some expensive ﬁrst-line cytotoxic drugs partially
subsidized by government, because cancer is one of
the top causes of mortality in Singapore. In recent
years, other expensive noncytotoxic drugs have
been included, e.g., angiotensin-converting enzyme
(ACE) inhibitors and long-acting calcium channel
blockers, which have been proven to be effective
ﬁrst-line treatment for hypertension. The current
number of drugs, exclusive of different strengths
and dosage forms, the in SDL stands at 455, includ-
ing 372 as SDL I and 83 as SDL II.
In addition, the MOH also publishes various
treatment guidelines based on an evidence-based
approach using the hierarchy of evidence as sug-
gested by the Cochrane Center. To date, 20 clinical
practice guidelines have been published, including
treatment guidelines for asthma, diabetes, oste-
oporosis, and hypertension [45–49].
Pharmacoeconomic Studies in the Literature
The major types of PE studies being carried out in
Singapore are cost-effectiveness studies and the
cost-of-illness studies. The clinical probabilities are
mainly those obtained from the literature supple-
mented by local data whenever available. Other OR
includes publications on the validation of several
health-related quality-of-life instruments [50–52].
In performing PE studies, cost information has
been obtained from the MOH based on DRGs for
inpatients, which are updated at regular intervals,
and charges for outpatient attendance, which are
established nationally by the MOH.
The Government’s Perspective
As mentioned in the previous section, the MOH in
Singapore maintains an SDL. At present, there are
no formal PE requirements for inclusion into the
SDL; hence, there are no formal guidelines for the
conduct of PE studies. Nevertheless, attempts have
been made to include ﬁnancial data and some
rudimentary PE evaluation in the decision-making
process.
The Perspective from Academia
In Singapore, academic training for PE is being con-
ducted mainly at the Department of Pharmacy at
the National University of Singapore. Pharmacy
students are given a brief introduction to the con-
cept of PE at the undergraduate level during their
ﬁnal year of their 4-year course of study. The stu-
dents attend approximately 10 hours of didactic
instruction. The Department of Pharmacy also
offers a PE module at the graduate level that runs
for a whole semester.
The Pharmaceutical Society of Singapore also
organizes workshops on how to apply the principles
of PE in the practice of pharmacy in an ad hoc man-
ner by inviting academics from the university to
conduct the workshops. At present, the lack of a
critical mass of researchers in the area, full appre-
ciation of the potential importance and application
of PE studies, and relatively poor technical skill of
the health-care professionals, especially among the
pharmacists, are the main barriers to advancing the
ﬁeld at a more rapid pace [53].
The academic community has not at this juncture
been involved in development of guidelines for con-
ducting PE studies. Nevertheless, as mentioned in
the previous section, the Center for Pharmaceutical
Administration has set up the Pharmacoeconomics
and Drug Utilization Unit and has planned to apply
PE principles in assisting in the decision of drug
inclusion into the SDL. It is likely that at least an
informal guideline will be developed in the process.
In view of the relative lack of available PE exper-
tise in the public sector in Singapore, it is envisaged
that in the near future, the academic community
will be involved in the development of guidelines for
PE evaluation as the MOH is moving toward the
direction of applying PE principles in evaluating
applications for inclusion into the SDL. Neverthe-
less, the extent of involvement of the academic
community in the evaluation of PE studies is still
evolving.
Prospects for the Future
During the past few years, the Singaporean govern-
ment has introduced several measures to reform
health-care delivery in Singapore. These include the
introduction of DRG funding for inpatient treat-
ment in October 1999 and the regrouping of the
public hospitals into two major clusters, National
Healthcare Group (NHG) and Singapore Health
Services (SHS) to improve efﬁciency through econ-
omy of scale in March 2000. Recently in March
2001, the MOH formed a task force to review the
drug prices in Singapore. One of the recommenda-
tions of the task force was to review the role of the
SDL in health-care delivery.
As mentioned previously, the concept of cost-
effectiveness has been considered in the decision-
making process of drug inclusion into the SDL,
although no formal PE studies have yet been
required for the decision process in granting subsi-
dies. The government is reviewing the funding and
ﬁnancing of the SDL and it is likely that the MOH
will adopt PE principles in the decision-making
process for drug inclusion in the SDL. This is shown
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by the fact that at the national level, the Center for
Pharmaceutical Administration (CPA) has recently
set up a Pharmacoeconomic and Drug Utilization
Unit in 2001. At the local level, the western cluster
of public hospitals, National Healthcare Group, is
planning to implement formal PE studies for drugs
that are applying for inclusion in their formulary.
Therefore, it is likely that PE data will become more
important in deciding drug inclusion for the SDL
and the formulary of the hospital clusters.
Taiwan
Before the inception of NHI, the Republic of
China’s (ROC) social insurance was divided into
three major sectors: labor insurance, government
employee insurance, and farmer health insurance.
In 1994, the Bureau of National Health Insurance
Organizational Statute was passed, and the Bureau
of National Health Insurance (BNHI) was formally
established on January 1, 1995, as the statutory
insurer in charge of NHI operations. The NHI
program ofﬁcially started on March 1, 1995, in
Taiwan.
The NHI program targets all ROC citizens as
beneﬁciaries. At the end of the year 2000, 21.4 mil-
lion people were enrolled in the NHI plan, account-
ing for 96.2% of the target population. The
reimbursement of medical resources utilization was
initially by FFS on both inpatient and outpatient
services. Starting in 1998, a case mix payment
methodology was introduced for 50 procedures and
surgeries. Dental care was reimbursed by a global
budget system in 1998. Then, a global budget meth-
odology was later implemented for Chinese medi-
cines (2000), primary care (2001), and then ﬁnally
hospital care (2002). Renal dialysis and respiratory
care by ventilator are still reimbursed by a per-diem
method.
Table 3 presents medical resources used in out-
patient care, both by primary care and by outpa-
tient clinics afﬁliated with hospitals [54]. Drug
expenditures were 33.0% to 34.6% of the total
outpatient care in these 4 years. Dispensing fees
increased signiﬁcantly from 1997 to 1999 owing to
the increase in the number of prescriptions. Drugs
used in inpatient care accounted for approximately
15.5% of the total inpatient care costs, and approx-
imately 25% of health-care expenditures were spent
on nontraditional Chinese medicine in Taiwan dur-
ing this period
Currently in Taiwan, there are at least three
methods used to determine the price of to-be-listed
new pharmaceutical products: the international Ta
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median price of 10 countries, the international
price ratio using comparator(s), and the treatment
course or daily cost using comparator. The 10
countries used to assess the international median
price are the United States, Canada, the United
Kingdom, Germany, Sweden, Belgium, Switzerland,
France, Australia, and Japan. Advantages or disad-
vantages of the new product on efﬁcacy, dosage
form, or pharmacokinetic proﬁle are considered for
additions or deductions to the price. In a few cir-
cumstances, the lowest price from among the 10
comparison countries or a price-volume negotiation
strategy is used by the government. The estimated
time needed from submission to public announce-
ment of the reimbursement price is from 3 to
6 months. Upon receiving the notice from the
BNHI concerning the price approval, pharmaceuti-
cal companies must reply to the BNHI as to
whether the price is accepted or not within 7 days.
The reimbursement price is guaranteed for 1 year.
During that year, the only mechanism of price cut is
through a price-volume survey. Nothing else can
change the price once it has been established in this
ﬁrst year.
Pharmaceutical companies provide evidence to
be evaluated by experts invited by the BNHI and the
Pharmacy Beneﬁt Committee. Results from rand-
omized controlled clinical trials are required, with a
preference for published head-to-head comparisons
of efﬁcacy and safety. PE evidence is encouraged.
PE Studies in the Literature
Until July 2002, only one new drug product,
donepezil, had completed the evaluation process for
the BNHI with local PE evidence attached. Accord-
ing to the BNHI, if the estimated market of a new
product exceeds NT$100 million/year (New Tai-
wan dollars or US$3 million/year), then a price-
volume negotiation strategy can be considered. The
BNHI will negotiate the price of the new product
with the pharmaceutical company for 3 years and,
at the end of the third year, a PE study would be
completed and used to determine a new price. The
study would need to include cost and outcomes data
for the Taiwanese population. If a new product is
ﬁrst introduced to the Taiwan market, a PE study is
recommended by the BNHI. Owing to the lack of
experience by local physicians, the PE data can be
referenced from overseas literature. Nevertheless,
local cost data are required in the modeling study.
Currently, several PE studies are ongoing within
a number of international pharmaceutical compa-
nies in Taiwan. Hepatitis prevalence and its treat-
ment, for example, are major issues in Taiwan.
Approximately 20% of Taiwanese population have
hepatitis B, and 2.9% to 5.4% have hepatitis C
[55,56]. Both hepatitis B and C have new drug
products on the market, and they are expensive.
Therefore, the BNHI needs to decide whether or not
to reimburse the new drug products. Also, owing to
the global budget system, and the forthcoming
implementation of a DRG reimbursement system,
as well as the trend toward disease management,
cost-effective treatments are generating an increas-
ing amount of interested at the BNHI and among
hospital managers and medical practitioners. Thus,
it is believed that economic evaluations will be an
important issue for academia, industry, and health-
care decision makers in the next decade.
The Government’s Perspective
The development of a standardized mechanism for
economic evaluation is still at the beginning stages
in Taiwan. Guidelines published from Canada and
Australia were reviewed; however, standardization
is still in progress. Experts in this ﬁeld are uncom-
mon and few scholars from academia have been
organized by the BNHI to develop the evaluation
procedures. Nevertheless, the BNHI has expressed
strong support of the mechanism of economic
evaluation. From the Canadian experience, the
BNHI is trying to develop a Taiwan Coordinating
Ofﬁce for Health Technology Assessment (TCO-
HTA). A written document outlining this effort
and highlighting the strong commitment of BNHI
regarding PE evaluation is under development.
The organization of several academic groups to
help in evaluation process is under way. Initially,
two groups will be formed a therapeutic evalua-
tion group and an economic evaluation group at
the ﬁrst stage.
At this time, only one school of pharmacy has PE
courses taught at the graduate level. This program is
new, established just 2 years ago. Five professors in
the public health arena have training in health eco-
nomics and are interested in exploring the ﬁeld.
Additionally, one new association named the Tai-
wan Society for Pharmacoeconomics and Outcomes
Research (TASPOR) was organized. Members have
been recruited since the government approval of
this organization on August 9, 2002. The health-
care system in Taiwan is facing the need of eco-
nomic evaluation on medical device, procedures,
and drug treatments. The planning of organiza-
tional structure, the academic research groups, the
research manpower training, the Association, and
the pharmaceutical industry are all aware and
became more accepting.
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Owing to the global budget system, and the
forthcoming implementation of a DRG reimburse-
ment system, as well as the trend toward disease
management, cost-effective treatments are generat-
ing an increasing amount of interested at the BNHI
and among hospital managers and medical practi-
tioners. Thus, it is believed that economic evalua-
tions will be an important issue for academia,
industry, and health-care decision makers in the
next decade.
Discussion
Asia is known for its diversity in terms of social
and economic development, ethnicity, population
size, health-care system, culture, language, and reli-
gion. The speed of adoption of PE is highly sensi-
tive to local situations and, as this article
illustrates, the rate of adoption has been quite var-
iable across Asia. There are some countries that are
progressing quite quickly along the path of devel-
opment of governmental requirements for PE data
in the approval process for new pharmaceuticals.
Academic circles are being newly established in
most countries and are expanding in size with a
growing number of PE courses being taught and in
some cases full PE departments being established.
A few pharmaceutical companies have established
departments of OR in the region or are assigning
global headquarters staff to liaison positions for
Asia. The number of PE publications is quite large
in some countries and not that far from some
European countries in terms of annual publica-
tions. Still there appear to be a number of chal-
lenges being faced across Asia.
One challenge that may be more relevant to Asia
in general is data availability. As was indicated in
many of these country reports, local data sources
for things such as medical efﬁcacy of the new tech-
nologies and epidemiologic databases are in short
supply.
Another challenge, which is perhaps particularly
acute for international pharmaceutical companies,
is how to incorporate PE elements into the clinical
trials being conducted in Asian countries. Whereas
the medical component of a clinical trial may be
repeatable across countries, there is no one-size-ﬁts-
all approach for PE components, because the diver-
sity among these countries particularly the data
sources will most likely require country-speciﬁc
study designs.
A third challenge relates to the interpretation of
PE results. This challenge is twofold: 1) when there
are no local data, how do researchers bridge results
from other countries to the local situation? 2) When
the data are generated from the local Asian region,
how can the results be generalized to other Asian
countries? This is perhaps particularly acute in Asia
because it is often not among the ﬁrst regions cho-
sen for initial drug development/registration.
In summary, there are challenges but none too
large to block the progress of the use of PE in Asia.
Learning the lessons that other countries have gone
through will be an advantage that all Asian coun-
tries can beneﬁt from as they continue to adapt the
concepts of PE and OR. Certainly the driving forces
that have ushered PE into the mainstream in west-
ern countries such as rapid health-care inﬂation and
an aging population are also present in Asia, and
these will likely form the underpinnings for the con-
tinued development and growth of PE research in
Asia as well.
The authors are indebted to the editorial assistance
offered by Anne Mc Racey, Kathleen R. Melia, and Paul
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